Obesity Author: George A. Bray, MD
Editorial changes - 2009-11-18
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
Diagnosis
  • Use history to obtain information about risk factors for obesity.
  • Use physical examination to establish the presence of obesity, central adiposity, and associated comorbid conditions.
  • Use laboratory testing to confirm clinical evaluation and to assess for presence of comorbidities.
  • Consider the broad range of conditions associated with unhealthy weight.
History and Physical Examination Elements for Obesity (table)
Laboratory and Other Studies for Obesity (table)
Differential Diagnosis of Obesity (table)


Use history to obtain information about risk factors for obesity. B

Background | Back to top


Use physical examination to establish the presence of obesity, central adiposity, and associated comorbid conditions. A

Background | Back to top


Use laboratory testing to confirm clinical evaluation and to assess for presence of comorbidities. BC

  • In all patients with a BMI >25 kg/m2 or associated comorbid conditions, obtain:
    • Blood for glucose, creatinine levels
    • Lipid profile including HDL cholesterol, triglycerides, LDL cholesterol levels
    • Sleep test to confirm sleep apnea in patients with somnolence, plethora, or history of snoring
    • Ultrasound to screen for gallstones and hepatic fat
  • Assess patients for the presence of metabolic syndrome.
  • See table Laboratory and Other Studies for Obesity.
  • See table Clinical Features of the Metabolic Syndrome
Background | Back to top


Consider the broad range of conditions associated with unhealthy weight. A

Background | Back to top

FAQs
George A. Bray, MD, is a speaker for Eli Lilly, Amylin Corp., and Merck & Co., received grants from Merck & Co., and Takeda Pharmaceuticals; and has consulted for Sanofi-Aventis, Merck, and Amylin.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.